Free Trial

Neurocrine Biosciences (NBIX) Competitors

Neurocrine Biosciences logo
$119.57 +0.45 (+0.38%)
As of 12:30 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

NBIX vs. ALNY, BIIB, UTHR, INCY, EXEL, BMRN, EXAS, RGEN, HALO, and MDGL

Should you be buying Neurocrine Biosciences stock or one of its competitors? The main competitors of Neurocrine Biosciences include Alnylam Pharmaceuticals (ALNY), Biogen (BIIB), United Therapeutics (UTHR), Incyte (INCY), Exelixis (EXEL), BioMarin Pharmaceutical (BMRN), Exact Sciences (EXAS), Repligen (RGEN), Halozyme Therapeutics (HALO), and Madrigal Pharmaceuticals (MDGL). These companies are all part of the "biotechnology" industry.

Neurocrine Biosciences vs.

Neurocrine Biosciences (NASDAQ:NBIX) and Alnylam Pharmaceuticals (NASDAQ:ALNY) are both large-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, earnings, analyst recommendations, risk, valuation, community ranking and media sentiment.

Neurocrine Biosciences has a net margin of 14.49% compared to Alnylam Pharmaceuticals' net margin of -12.37%. Neurocrine Biosciences' return on equity of 13.38% beat Alnylam Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Neurocrine Biosciences14.49% 13.38% 9.73%
Alnylam Pharmaceuticals -12.37%N/A -6.83%

Neurocrine Biosciences currently has a consensus price target of $162.00, suggesting a potential upside of 36.00%. Alnylam Pharmaceuticals has a consensus price target of $319.17, suggesting a potential upside of 10.44%. Given Neurocrine Biosciences' stronger consensus rating and higher probable upside, equities analysts clearly believe Neurocrine Biosciences is more favorable than Alnylam Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Neurocrine Biosciences
0 Sell rating(s)
3 Hold rating(s)
19 Buy rating(s)
0 Strong Buy rating(s)
2.86
Alnylam Pharmaceuticals
1 Sell rating(s)
4 Hold rating(s)
21 Buy rating(s)
0 Strong Buy rating(s)
2.77

Neurocrine Biosciences has higher revenue and earnings than Alnylam Pharmaceuticals. Alnylam Pharmaceuticals is trading at a lower price-to-earnings ratio than Neurocrine Biosciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Neurocrine Biosciences$2.41B4.89$341.30M$2.9540.38
Alnylam Pharmaceuticals$2.35B16.05-$278.16M-$2.09-138.28

Alnylam Pharmaceuticals received 123 more outperform votes than Neurocrine Biosciences when rated by MarketBeat users. However, 77.68% of users gave Neurocrine Biosciences an outperform vote while only 76.32% of users gave Alnylam Pharmaceuticals an outperform vote.

CompanyUnderperformOutperform
Neurocrine BiosciencesOutperform Votes
1044
77.68%
Underperform Votes
300
22.32%
Alnylam PharmaceuticalsOutperform Votes
1167
76.32%
Underperform Votes
362
23.68%

In the previous week, Alnylam Pharmaceuticals had 1 more articles in the media than Neurocrine Biosciences. MarketBeat recorded 20 mentions for Alnylam Pharmaceuticals and 19 mentions for Neurocrine Biosciences. Neurocrine Biosciences' average media sentiment score of 1.40 beat Alnylam Pharmaceuticals' score of 1.27 indicating that Neurocrine Biosciences is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Neurocrine Biosciences
17 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Alnylam Pharmaceuticals
14 Very Positive mention(s)
2 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

92.6% of Neurocrine Biosciences shares are owned by institutional investors. Comparatively, 93.0% of Alnylam Pharmaceuticals shares are owned by institutional investors. 4.3% of Neurocrine Biosciences shares are owned by insiders. Comparatively, 1.5% of Alnylam Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Neurocrine Biosciences has a beta of 0.26, indicating that its stock price is 74% less volatile than the S&P 500. Comparatively, Alnylam Pharmaceuticals has a beta of 0.17, indicating that its stock price is 83% less volatile than the S&P 500.

Summary

Neurocrine Biosciences beats Alnylam Pharmaceuticals on 13 of the 18 factors compared between the two stocks.

Get Neurocrine Biosciences News Delivered to You Automatically

Sign up to receive the latest news and ratings for NBIX and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

NBIX vs. The Competition

MetricNeurocrine BiosciencesBiological Products IndustryMedical SectorNASDAQ Exchange
Market Cap$11.79B$2.93B$5.33B$8.39B
Dividend YieldN/A1.64%5.21%4.11%
P/E Ratio36.2131.1826.7119.71
Price / Sales4.89398.78386.46120.65
Price / Cash34.35168.6838.2534.62
Price / Book4.593.236.774.50
Net Income$341.30M-$72.35M$3.23B$248.22M
7 Day Performance-1.57%2.49%0.48%-0.78%
1 Month Performance15.34%2.45%9.10%11.53%
1 Year Performance-15.22%-24.98%18.56%8.99%

Neurocrine Biosciences Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
NBIX
Neurocrine Biosciences
4.8714 of 5 stars
$119.57
+0.4%
$162.00
+35.5%
-14.6%$11.83B$2.41B36.321,200Positive News
ALNY
Alnylam Pharmaceuticals
4.1797 of 5 stars
$291.86
+2.3%
$319.17
+9.4%
+91.5%$38.06B$2.35B-134.502,000Positive News
BIIB
Biogen
4.8942 of 5 stars
$129.44
+3.1%
$191.30
+47.8%
-43.9%$18.97B$9.82B11.578,720Positive News
UTHR
United Therapeutics
4.9772 of 5 stars
$305.31
0.0%
$392.00
+28.4%
+11.7%$13.77B$2.99B13.41980Positive News
Analyst Revision
INCY
Incyte
4.8728 of 5 stars
$63.81
+0.8%
$73.53
+15.2%
+10.8%$12.35B$4.41B236.342,320Positive News
EXEL
Exelixis
4.094 of 5 stars
$44.69
-1.6%
$38.94
-12.9%
+104.1%$12.19B$2.30B25.251,220Positive News
Insider Trade
BMRN
BioMarin Pharmaceutical
4.9421 of 5 stars
$59.41
+0.2%
$93.45
+57.3%
-24.1%$11.39B$2.95B27.003,080Positive News
Insider Trade
EXAS
Exact Sciences
4.6351 of 5 stars
$56.94
+0.9%
$70.90
+24.5%
+5.6%$10.74B$2.83B-10.226,400Positive News
RGEN
Repligen
4.821 of 5 stars
$126.19
-0.2%
$173.25
+37.3%
-27.1%$7.09B$650.43M-247.432,020Positive News
Gap Down
HALO
Halozyme Therapeutics
4.8553 of 5 stars
$53.29
+2.4%
$61.90
+16.2%
+18.2%$6.57B$1.08B15.54390
MDGL
Madrigal Pharmaceuticals
4.5252 of 5 stars
$290.72
-0.1%
$416.33
+43.2%
+16.3%$6.45B$317.38M-11.5990Positive News

Related Companies and Tools


This page (NASDAQ:NBIX) was last updated on 5/23/2025 by MarketBeat.com Staff
From Our Partners